A clinical-stage pharmaceutical company developing a new class of cognitive-enhancing small molecules: nomethiazoles, which act as nitric oxide donor prodrugs and GABA(A) positive allosteric modulators. This results in CREB activation, vasodilation, reduced neuroinflammation, and reduced excitotoxicity. This MoA is neuroprotective in many animal models of CNS disease and cognitive decline. Revivo has been funded by the NIH, ADDF, and private venture capital, and we are raising capital for our clinical trials now.